Evidence map›Paper›PMID 41102175›Full record

ArticleNature communications2025

Enhancing cap-independent translation of linear mRNA.

Sebastian Golojuch, Brendan Largey, Afaf H El-Sagheer, Tom Brown

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Enhancement of Therapeutic mRNA Translation in Cellular Stress Conditions.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sebastian GolojuchDepartment of Chemistry, Chemistry Research Laboratory, University of Oxford, Oxford, UK. sebastian.golojuch@chem.ox.ac.uk.ORCID http://orcid.org/0000-0003-1117-3401
Brendan LargeyDepartment of Chemistry, Chemistry Research Laboratory, University of Oxford, Oxford, UK.
Afaf H El-SagheerDepartment of Chemistry, Chemistry Research Laboratory, University of Oxford, Oxford, UK. ahes@soton.ac.uk.ORCID http://orcid.org/0000-0001-8706-1292
Tom BrownDepartment of Chemistry, Chemistry Research Laboratory, University of Oxford, Oxford, UK. tom.brown@chem.ox.ac.uk.ORCID http://orcid.org/0000-0002-6538-3036

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions) 861381
6 · The paper itself

Abstract

While cap-dependent translation remains the primary focus in mRNA-based therapeutics, cap-independent translation holds promise for targeting diseases ranging from cancer to neurodegeneration. However, cap-independently translated mRNAs are unstable, produce less protein than capped mRNAs, and current methods for their improvement are imperfect. Here, we propose the use of in vitro transcription priming with azido-modified dinucleotide primer and post-transcriptional modification utilising click chemistry to improve the properties of cap-independently translated mRNAs. Our results demonstrate a significant enhancement in mRNA stability and protein output without eliciting immunogenicity. Moreover, we show how the mRNA 5'-end modification strategy can be used to investigate transfection and cap-independent translation processes in cells overcoming burdens associated with previous methods. Together, our findings support cap-independent translation as a viable alternative to the established cap-dependent process and provide tools for further exploration and enhancement of this modality.

Indexed as

Protein BiosynthesisRNA CapsRNA, MessengerClick ChemistryHEK293 CellsHumansRNA StabilityTranscription, GeneticTransfectionRNA CapsRNA, Messenger

Identifiers

PMID41102175
PMCPMC12532787

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.